See what’s new.
Duke Translational Chaperones help researchers secure over $6.5M in translational funding
In their pilot year, the new team at OTC worked with Duke life sciences PIs to position their research for maximal translational impact. Who will they help next?
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
How old are you, really? Biological aging tech from Duke inventors spotlighted on TV
Professors Terrie Moffitt and Avshalom Caspi (Psychology & Neuroscience, Trinity) are leading experts in biological aging and have invented a test that is now a commercial product.
Seeds of Hope – Duke Magazine
Dr. Darell Bigner journeys from the farm to the heights of neuro-oncology and back again
Greenlight Health Data Solutions and Pattern Health Merge to Expand Healthcare, Life Sciences and Insurance Solutions
Pattern Health has licensed numerous technologies from Duke inventors, primarily clinical trial management software and supporting materials from the Duke University School of Medicine.
Invented at Duke 2024 showcases the past and present of innovation at Duke, promising a bright future
A special Centennial edition of Invented at Duke featured inventors and innovations from the past, present, and future of Duke.
BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
DANNCE.ai, a start-up from the lab of Assistant Professor Timothy Dunn (BME, Pratt), is also in the Duke Capital Partners portfolio.